Related Experiment Video
Updated: Feb 7, 2026

EEG Mu Rhythm in Typical and Atypical Development
Published on: April 9, 2014
Anticomplement Treatment in Atypical and Typical Hemolytic Uremic Syndrome
Fadi Fakhouri1, Chantal Loirat2
1Department of Nephrology and Immunology, Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes and Centre Hospitalier Universitaire de Nantes, Nantes, France.
Abstract:
The dissection of the pathogenic mechanisms of the various forms of the hemolytic uremic syndrome (HUS) has paved the way for the design of specific efficacious treatments. Such mechanistic approach led to a revolution in the management of atypical HUS with the use of the first-in class C5 blocker, eculizumab. The availability of this anticomplement drug has also raised unsettled questions regarding the cost or burden and optimal duration of therapy and its use in secondary HUS. The efficacy of eculizumab in Shiga toxin producing Escherichia coli-associated HUS is not to date established and the results of ongoing prospective studies are eagerly awaited. Nevertheless, the emergence of anticomplement therapies (eculizumab and other drugs in development) has transformed our approach of HUS.
Related Concept Videos
Antipsychotic Drugs: Typical and Atypical Agents
Typical Model Studies
Nephrotic Syndrome I : Introduction
Acute Coronary Syndrome I: Introduction
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Restless Leg Syndrome and Night Terrors
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...

